source
- Mid-dose petrelintide shows strongest weight loss in phase-2 trial, paving way for pivotal studyRoche and Zealand Pharma released new phase-2 data for petrelintide, an amylin analog being developed for obesity treatment. In the Zupreme 1 trial, the 5 mg dose achieved the greatest mean weight…
- Patient death raises safety concerns before Bristol Myers lung drug readoutA patient died from a fatal liver injury while taking part in a trial of Bristol Myers Squibb's lung disease candidate. The company disclosed the incident in a May amendment to its trial documents…